Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study
Tristan Ferry, Anne Conrad, É. Senneville, Sandrine Roux, Céline Dupieux, Aurélien Dinh, Sébastien Lustıg, Sylvain Goutelle, Thomas Briot, Truong‐Thanh Pham, Florent Valour
Abstract
A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.
Topics & Concepts
MedicineCohortAntimicrobialInternal medicineAdverse effectGramMultiple drug resistanceProspective cohort studyImplantAntibioticsSurgeryMicrobiologyBacteriaGeneticsBiologyOrthopedic Infections and TreatmentsAntimicrobial Resistance in StaphylococcusSurgical site infection prevention